GlassScriptPhysician profile
Brittnee Spooner
NPI 1447038682
$787.62
in general payments reported to CMS, 2019-2025
13 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $146 · 2024: $225 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $787.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $165.24 | 2023-2025 | Mavenclad |
| Abbvie INC. | $159.52 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $143.55 | 2025 | Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $64.87 | 2025 | Hyqvia |
| Alexion Pharmaceuticals, INC. | $49.43 | 2024-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $47.84 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $34.62 | 2025 | Vyepti |
| Sk Life Science, INC. | $28.59 | 2025 | |
| Eisai INC. | $24.53 | 2024 | |
| Kyowa Kirin, INC. | $21.08 | 2025 | |
| Neurelis, INC. | $20.49 | 2024 | Valtoco |
| Novo Nordisk INC | $14.21 | 2024 | Rybelsus, Ozempic |
| Corcept Therapeutics | $13.65 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittnee Spooner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.